Alvaro Pinto

Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial www.annalsofoncology.org/article/S092...

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, dou... Despite treatment advances, most patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease progression to castration-resistant disease within 5 years. The placebo-controlle...

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study www.annalsofoncology.org/article/S092...

FDA Approves Expanded Label of Novartis’ Prostate Cancer Treatment, Pluvicto Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer.

Big news in prostate cancer treatment! The #FDA has expanded the label for Novartis #Pluvicto, now approved before chemotherapy for PSMA-positive metastatic castration-resistant prostate cancer. #TCSC #cancerresearch #prostatecancer #psmafore

www.appliedclinicaltrialsonline.com/view/fda-app...

Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers The development of novel radiographic and molecular modalities has significantly improved the assessment of tumor burden and minimal residual disease (MRD) in cancer. This is a comprehensive overview ...

Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers - European Urology www.europeanurology.com/article/S030...

Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1) PURPOSECisplatin-based neoadjuvant chemotherapy (NAC) followed by cystectomy is the standard of care for patients with muscle-invasive bladder cancer (MIBC). Mutations in DNA damage repair genes are a...

Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1) | Journal of Clinical Oncology ascopubs.org/doi/10.1200/...

Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial Addition of abiraterone acetate plus prednisone (AAP) to androgen deprivation therapy (ADT) with or without docetaxel (D) improved overall survival in patients with de novo metastatic castration sensi...

Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial - European Journal of Cancer www.ejcancer.com/article/S095...

Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis All investigated ablative methods continue to represent effective treatment choices in renal cell carcinoma, and these findings support multi-disciplinary discussions of these treatment methods, along...

Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis - The Lancet Oncology www.thelancet.com/journals/lan...

ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial To our knowledge, the RADIOSA trial represents the first randomised trial in the metachronous oligometastatic hormone-sensitive prostate cancer setting to report improved clinical progression-free sur...

ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial - The Lancet Oncology www.thelancet.com/journals/lan...

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicen... The addition of [177Lu] Lu-PSMA-617 to enzalutamide was associated with improved survival and some aspects of HRQOL in patients with high-risk metastatic castration-resistant prostate cancer. Our find...

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial - The Lancet Oncology www.thelancet.com/journals/lan...

Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis - European Urology www.europeanurology.com/article/S030...

Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials. ascopubs.org/doi/10.1200/...

Safety and efficacy of neoadjuvant durvalumab plus gemcitabine/cisplatin or carboplatin in patients with operable high-risk upper tract urothelial carcinoma: the iNDUCT trial. PURPOSEAfter radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), prognosis is poor for high-risk patients. This study evaluated safety and efficacy of neoadjuvant chemotherap...

Safety and efficacy of neoadjuvant durvalumab plus gemcitabine/cisplatin or carboplatin in patients with operable high-risk upper tract urothelial carcinoma: the iNDUCT trial. ascopubs.org/doi/10.1200/...

And that’s only in the case you’re “lucky enough” to get published!

FDA Approves Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors The FDA has approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult solid tumor nivolumab (Opdivo) indications.

“FDA Approves Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors”.
Great news for patients, more convenient treatments, and less time- and resource-consuming schedules. www.onclive.com/view/fda-app...

Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review www.europeanurology.com/article/S030...

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial ascopubs.org/doi/10.1200/...

Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-analysis with Bayesian Modeling of Treatment Histories Recommendations of first-line therapies for metastatic hormone-sensitive (mHSPC), nonmetastatic castrate-resistant (M0CRPC), and metastatic castrate-r…

Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-analysis with Bayesian Modeling of Treatment Histories www.sciencedirect.com/science/arti...

Excited to share the release of a new book on bladder cancer that I had the pleasure of editing together with Margaret Knowles, featuring contributions from multiple expert authors!

If you don’t allow prior taxanes, and your control arm also excludes chemo… then your trial results will have low external validity (if any), and patients treated in the trial may have been exposed to suboptimal systemic therapy.

85 people in here now, and growing - come and join us!

#Genitourinary #Oncology #GUonc #GUoncol #GUoncology #ProstateCancer #KidneyCancer #Urothelial #BladderCancer #PenileCancer #TesticularCancer #pcsm #kcsm #blcsm #tcsm #Medsky #Oncsky #Medtwitter

go.bsky.app/DtoXvaD

Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer This nonrandomized clinical trial evaluates the safety, pharmacokinetics, and preliminary efficacy of rogaratinib in combination with the programmed cell death 1 ligand 1 inhibitor atezolizumab in cis...

Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial jamanetwork.com/journals/jam...

Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis Several factors informed HTA outcomes for new cancer medicines. A high ESMO-MCBS score, defined as indicating substantial clinical benefit, increased the likelihood of a positive HTA outcome and shortened the interval between marketing authorisation and HTA outcome, and this association was not affected by other variables. Additional factors informing HTA outcomes include evidence uncertainties and unmet medical need. Country-relevant differences exist in the time-to-HTA outcome and the propensity of some countries to achieve positive (restricted or unrestricted) outcomes compared with others.

Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis www.thelancet.com/journals/lan...

Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study Compared with White patients, Black patients had similar ICI effectiveness and lower toxicities among those treated in the national VHA system, potentially reflecting an important difference in the therapeutic ratio (ratio of benefit to harm) of ICIs. Our findings of decreased toxicity among Black patients require further investigation to assess their generalisability.

Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study www.thelancet.com/journals/lan...

Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma Belzutifan is a first-in-class hypoxia-inducible factor subunit 2α (HIF-2α) inhibitor approved at a dose of 120 mg once daily for certain adults with …

Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma www.sciencedirect.com/science/arti...

Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial Metastatic castration-resistant prostate cancer (mCRPC) typically exhibits resistance to immune checkpoint inhibitors (ICIs). However, a subset of mCR…

Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial www.sciencedirect.com/science/arti...

Implementing evidence‐based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024 To address the nuanced questions related to prostate cancer management that are unanswered by prospective trials but nonetheless encountered in day-to-day practice, the US Prostate Cancer Conference ...

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024 acsjournals.onlinelibrary.wiley.com/doi/10.1002/...

UK will have men's health strategy, government announces The strategy may cover areas such as mental health, suicide prevention, heart disease and stroke.

🚹 UK government to announce #MensHealth strategy.

🚹 “We’re seeing mental ill health on the rise and the shocking fact that #suicide is the biggest killer for men under 50.”

🚹 “Preventable killers like #heartdisease and #prostatecancer are being caught far too late."

www.bbc.com/news/article...

Only a subset of patients respond to immunotherapy

Why? Which ones?

We conducted an unbiased analysis of response biomarkers and found that hundreds of possible biomarkers collapse into five latent, orthogonal factors that underlie immunotherapy response.

www.nature.com/articles/s41...

Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies Abstract. Lineage plasticity and histologic transformation from prostate adenocarcinoma to neuroendocrine prostate cancer (NEPC) occurs in up to 15-20% of patients with castration-resistant prostate c...

Just in time for Thanksgiving, nice pathology framework for characterizing treatment emergent neuroendocrine #ProstateCancer, a biologically diverse entity that everyone has a hard time describing, in CCR - thanks to Michael Haffner and @mishabeltran.bsky.social
aacrjournals.org/clincancerre...

Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274 | Journal of Clinical Oncology Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or sec...

Extended follow up of adjuvant Nivolumab study Checkmate-274 in urothelial tumors confirms DFS improvement both in ITT and PD-L1+ population... and OS data is going in the right direction. ascopubs.org/doi/pdf/10.1...